Primaura Therapeutics today announced its launch with a mission to develop next-generation genomic medicines that precisely restore physiological protein
Engineering translation
to restore protein balance
Engineering translation
to restore protein balance
THE CHALLENGE
When disease is
a matter of dosage
For many genetic diseases, the challenge is not whether a protein is present, but whether it is produced at the correct level. Both insufficient and excessive protein expression can have profound biological consequences.
Primaura Therapeutics is developing technologies designed to precisely modulate endogenous protein production, aiming to restore physiological balance.
THE CHALLENGE
When disease is
a matter of dosage
For many genetic diseases, the challenge is not whether a protein is present, but whether it is produced at the correct level. Both insufficient and excessive protein expression can have profound biological consequences.
Primaura Therapeutics is developing technologies designed to precisely modulate endogenous protein production, aiming to restore physiological balance.
OUR PLTAFORM
BOOST 2.0
BOOST 2.0 is Primaura Therapeutics’ proprietary genome-editing platform designed to precisely modulate endogenous protein expression.
Rather than replacing genes or introducing exogenous DNA, BOOST 2.0 targets the Kozak sequence (a key regulator of translation initiation) to fine tune protein production directly at its source.
Many rare genetic diseases are caused by haploinsufficiency, where a single functional copy of a gene is not sufficient to maintain normal function. BOOST 2.0 enhances expression of the remaining healthy copy, offering a mutation-agnostic therapeutic approach that could serve broad patient populations without requiring a therapy tailored to each individual mutation.
By restoring physiological protein levels, BOOST 2.0 aims to address the underlying cause of gene-dosage disorders through a precise and potentially durable therapeutic strategy.
Learn more
OUR PLTAFORM
BOOST 2.0
BOOST 2.0 is Primaura Therapeutics’ proprietary genome-editing platform designed to precisely modulate endogenous protein expression.
Rather than replacing genes or introducing exogenous DNA, BOOST 2.0 targets the Kozak sequence (a key regulator of translation initiation) to fine tune protein production directly at its source.
Many rare genetic diseases are caused by haploinsufficiency, where a single functional copy of a gene is not sufficient to maintain normal function. BOOST 2.0 enhances expression of the remaining healthy copy, offering a mutation-agnostic therapeutic approach that could serve broad patient populations without requiring a therapy tailored to each individual mutation.
By restoring physiological protein levels, BOOST 2.0 aims to address the underlying cause of gene-dosage disorders through a precise and potentially durable therapeutic strategy.
Learn more
PRECISION
BOOST 2.0 precisely edits the Kozak sequence to fine-tune endogenous protein production while preserving the native genomic context.
BALANCE
Rather than simply increasing or silencing gene activity, BOOST 2.0 is designed to restore protein expression toward physiological levels.
PLATFORM
By targeting a common regulatory mechanism of translation, BOOST 2.0 has the potential to address multiple dosage-sensitive disorders.
PRECISION
BOOST 2.0 precisely edits the Kozak sequence to fine-tune endogenous protein production while preserving the native genomic context.
BALANCE
Rather than simply increasing or silencing gene activity, BOOST 2.0 is designed to restore protein expression toward physiological levels.
PLATFORM
By targeting a common regulatory mechanism of translation, BOOST 2.0 has the potential to address multiple dosage-sensitive disorders.
LATEST NEWS
Advancing the future
of protein expression
LATEST NEWS
Advancing the future
of protein expression
Primaura Therapeutics today announced its launch with a mission to develop next-generation genomic medicines that precisely restore physiological protein